All these promising roles of SGLT2 inhibitors in cardiovascular disease management were reflected in the latest European Society of Cardiology (ESC) guidelines, which state that SGLT2 inhibitors should be the basis of pharmacological management for heart failure, independent of a patient's diabetic status [11]. This evidence concerns the gene SLC5A2 and heart failure.